» Articles » PMID: 36532069

Putative Critical Quality Attribute Matrix Identifies Mesenchymal Stromal Cells with Potent Immunomodulatory and Angiogenic "fitness" Ranges in Response to Culture Process Parameters

Overview
Journal Front Immunol
Date 2022 Dec 19
PMID 36532069
Authors
Affiliations
Soon will be listed here.
Abstract

Adipose-derived mesenchymal stromal cells (MSC(AT)) display immunomodulatory and angiogenic properties, but an improved understanding of quantitative critical quality attributes (CQAs) that inform basal MSC(AT) fitness ranges for immunomodulatory and/or angiogenic applications is urgently needed for effective clinical translation. We constructed an matrix of multivariate readouts to identify putative CQAs that were sensitive enough to discriminate between specific critical processing parameters (CPPs) chosen for their ability to enhance MSC immunomodulatory and angiogenic potencies, with consideration for donor heterogeneity. We compared 3D aggregate culture conditions (3D normoxic, 3D-N) and 2D hypoxic (2D-H) culture as non-genetic CPP conditions that augment immunomodulatory and angiogenic fitness of MSC(AT). We measured multivariate panels of curated genes, soluble factors, and morphometric features for MSC(AT) cultured under varying CPP and licensing conditions, and we benchmarked these against two functional and therapeutically relevant anchor assays - monocyte/macrophage (MΦ) polarization and angiogenesis. Our results showed that varying CPP conditions was the primary driver of MSC(AT) immunomodulatory fitness; 3D-N conditions induced greater MSC(AT)-mediated MΦ polarization toward inflammation-resolving subtypes. In contrast, donor heterogeneity was the primary driver of MSC(AT) angiogenic fitness. Our analysis further revealed panels of putative CQAs with minimum and maximum values that consisted of twenty MSC(AT) characteristics that informed immunomodulatory fitness ranges, and ten MSC(AT) characteristics that informed angiogenic fitness ranges. Interestingly, many of the putative CQAs consisted of angiogenic genes or soluble factors that were inversely correlated with immunomodulatory functions (, , , , and genes), and positively correlated to angiogenic functions (VEGF protein), respectively. We applied desirability analysis to empirically rank the putative CQAs for MSC(AT) under varying CPP conditions and donors to numerically identify the desirable CPP conditions or donors with maximal MSC(AT) immunomodulatory and/or angiogenic fitness. Taken together, our approach enabled combinatorial analysis of the matrix of multivariate readouts to provide putative quantitative CQAs that were sensitive to variations in select CPPs that enhance MSC immunomodulatory/angiogenic potency, and donor heterogeneity. These putative CQAs may be used to prospectively screen potent MSC(AT) donors or cell culture conditions to optimize for desired basal MSC(AT) immunomodulatory or angiogenic fitness.

Citing Articles

Mesenchymal stromal cell therapies for traumatic neurological injuries.

Wang X, Wang Q, Xia Z, Yang Y, Dai X, Zhang C J Transl Med. 2024; 22(1):1055.

PMID: 39578845 PMC: 11583761. DOI: 10.1186/s12967-024-05725-3.


The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.

cesnik A, Svajger U Front Cell Dev Biol. 2024; 12:1400347.

PMID: 39129786 PMC: 11310176. DOI: 10.3389/fcell.2024.1400347.


Alexander Friedenstein, Mesenchymal Stem Cells, Shifting Paradigms and Euphemisms.

Phinney D Bioengineering (Basel). 2024; 11(6).

PMID: 38927770 PMC: 11201071. DOI: 10.3390/bioengineering11060534.


Impacts of priming on distinct immunosuppressive mechanisms of mesenchymal stromal cells under translationally relevant conditions.

Herger N, Heggli I, Mengis T, Devan J, Arpesella L, Brunner F Stem Cell Res Ther. 2024; 15(1):65.

PMID: 38443999 PMC: 10916130. DOI: 10.1186/s13287-024-03677-5.


Macrophage polarization in osteoarthritis progression: a promising therapeutic target.

Zhang Y, Ji Q Front Cell Dev Biol. 2023; 11:1269724.

PMID: 37954210 PMC: 10639142. DOI: 10.3389/fcell.2023.1269724.


References
1.
Miceli V, Pampalone M, Vella S, Carreca A, Amico G, Conaldi P . Comparison of Immunosuppressive and Angiogenic Properties of Human Amnion-Derived Mesenchymal Stem Cells between 2D and 3D Culture Systems. Stem Cells Int. 2019; 2019:7486279. PMC: 6397962. DOI: 10.1155/2019/7486279. View

2.
Chinnadurai R, Rajan D, Qayed M, Arafat D, Garcia M, Liu Y . Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. Cell Rep. 2018; 22(9):2504-2517. PMC: 5855117. DOI: 10.1016/j.celrep.2018.02.013. View

3.
Czapla J, Matuszczak S, Kulik K, Wisniewska E, Pilny E, Jarosz-Biej M . The effect of culture media on large-scale expansion and characteristic of adipose tissue-derived mesenchymal stromal cells. Stem Cell Res Ther. 2019; 10(1):235. PMC: 6683465. DOI: 10.1186/s13287-019-1331-9. View

4.
Wobma H, Kanai M, Ma S, Shih Y, Li H, Duran-Struuck R . Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms. J Immunol Regen Med. 2018; 1:45-56. PMC: 6197483. DOI: 10.1016/j.regen.2018.01.001. View

5.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View